Clinical trial
A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors
NCT04521621 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 28, 2020
- Completion date
- July 25, 2023
- Enrollment
- 76 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.